Veracyte Statistics
Total Valuation
Veracyte has a market cap or net worth of $3.04 billion. The enterprise value is $2.78 billion.
Important Dates
The next confirmed earnings date is Monday, February 24, 2025, after market close.
| Earnings Date | Feb 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Veracyte has 77.50 million shares outstanding. The number of shares has increased by 4.20% in one year.
| Current Share Class | 77.50M |
| Shares Outstanding | 77.50M |
| Shares Change (YoY) | +4.20% |
| Shares Change (QoQ) | +1.69% |
| Owned by Insiders (%) | 0.41% |
| Owned by Institutions (%) | 104.07% |
| Float | 77.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 43.22 |
| PS Ratio | 6.94 |
| Forward PS | 6.26 |
| PB Ratio | 2.58 |
| P/TBV Ratio | 9.95 |
| P/FCF Ratio | 53.76 |
| P/OCF Ratio | 45.92 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 63.21, with an EV/FCF ratio of 49.26.
| EV / Earnings | n/a |
| EV / Sales | 6.54 |
| EV / EBITDA | 63.21 |
| EV / EBIT | 135.90 |
| EV / FCF | 49.26 |
Financial Position
The company has a current ratio of 5.08, with a Debt / Equity ratio of 0.02.
| Current Ratio | 5.08 |
| Quick Ratio | 4.59 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.37 |
| Debt / FCF | 0.35 |
| Interest Coverage | 5,118.00 |
Financial Efficiency
Return on equity (ROE) is -0.83% and return on invested capital (ROIC) is 1.13%.
| Return on Equity (ROE) | -0.83% |
| Return on Assets (ROA) | 1.07% |
| Return on Invested Capital (ROIC) | 1.13% |
| Return on Capital Employed (ROCE) | 1.70% |
| Revenue Per Employee | $521,879 |
| Profits Per Employee | -$11,372 |
| Employee Count | 815 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 7.08 |
Taxes
In the past 12 months, Veracyte has paid $1.10 million in taxes.
| Income Tax | 1.10M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +56.53% in the last 52 weeks. The beta is 1.71, so Veracyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.71 |
| 52-Week Price Change | +56.53% |
| 50-Day Moving Average | 42.17 |
| 200-Day Moving Average | 32.45 |
| Relative Strength Index (RSI) | 40.70 |
| Average Volume (20 Days) | 731,588 |
Short Selling Information
The latest short interest is 3.15 million, so 4.07% of the outstanding shares have been sold short.
| Short Interest | 3.15M |
| Short Previous Month | 3.05M |
| Short % of Shares Out | 4.07% |
| Short % of Float | 4.08% |
| Short Ratio (days to cover) | 3.96 |
Income Statement
In the last 12 months, Veracyte had revenue of $425.33 million and -$9.27 million in losses. Loss per share was -$0.12.
| Revenue | 425.33M |
| Gross Profit | 296.96M |
| Operating Income | 20.47M |
| Pretax Income | -54.79M |
| Net Income | -9.27M |
| EBITDA | 44.01M |
| EBIT | 20.47M |
| Loss Per Share | -$0.12 |
Full Income StatementBalance Sheet
The company has $274.08 million in cash and $19.79 million in debt, giving a net cash position of $254.29 million or $3.28 per share.
| Cash & Cash Equivalents | 274.08M |
| Total Debt | 19.79M |
| Net Cash | 254.29M |
| Net Cash Per Share | $3.28 |
| Equity (Book Value) | 1.18B |
| Book Value Per Share | 15.18 |
| Working Capital | 286.54M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $66.12 million and capital expenditures -$9.64 million, giving a free cash flow of $56.48 million.
| Operating Cash Flow | 66.12M |
| Capital Expenditures | -9.64M |
| Free Cash Flow | 56.48M |
| FCF Per Share | $0.73 |
Full Cash Flow StatementMargins
Gross margin is 69.82%, with operating and profit margins of 4.81% and -2.18%.
| Gross Margin | 69.82% |
| Operating Margin | 4.81% |
| Pretax Margin | -1.92% |
| Profit Margin | -2.18% |
| EBITDA Margin | 10.35% |
| EBIT Margin | 4.81% |
| FCF Margin | 13.28% |
Dividends & Yields
Veracyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.20% |
| Shareholder Yield | -4.20% |
| Earnings Yield | -0.31% |
| FCF Yield | 1.86% |
Dividend DetailsAnalyst Forecast
The average price target for Veracyte is $40.86, which is 4.29% higher than the current price. The consensus rating is "Buy".
| Price Target | $40.86 |
| Price Target Difference | 4.29% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 11.85% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Veracyte has an Altman Z-Score of 11.26 and a Piotroski F-Score of 6.
| Altman Z-Score | 11.26 |
| Piotroski F-Score | 6 |